WVP
SNDX icon

Worth Venture Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Worth Venture Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,900
Closed -$158K – 165
2023
Q3 		$158K Hold
10,900
– – 0.09% 112
2023
Q2 		$228K Buy
+10,900
New +$227K 0.12% 106

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Worth Venture Partners's SNDX Position: Q4 2023 in Review

Worth Venture Partners sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 10,900 shares — an estimated $158K sold.

Worth Venture Partners first reported a position in SNDX in Q2 2023 and held it in 2 quarters. The position peaked at $228K in Q2 2023. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Worth Venture Partners reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Worth Venture Partners sold 10,900 Syndax Pharmaceuticals shares in Q4 2023, an estimated $158K.
  • Worth Venture Partners first reported a position in Syndax Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Worth Venture Partners's Syndax Pharmaceuticals position peaked at $228K in Q2 2023.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Worth Venture Partners's 13F filing for Q4 2023, filed 9 Feb 2024.